{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T18:21:23Z","timestamp":1783621283890,"version":"3.55.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Laboratory Medicine"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.cll.2026.02.002","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T01:10:39Z","timestamp":1775178639000},"page":"167-183","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Advances in Hemophilia: New Treatments and Complications in Laboratory Testing\/Monitoring"],"prefix":"10.1016","volume":"46","author":[{"given":"Sibgha","family":"Zaheer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.cll.2026.02.002_bib1","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1093\/labmed\/lmx050","article-title":"Coagulation testing in the core laboratory","volume":"48","author":"Winter","year":"2017","journal-title":"Lab Med"},{"key":"10.1016\/j.cll.2026.02.002_bib2","doi-asserted-by":"crossref","unstructured":"Muller J., Miesbach F., Pruller T., et al., An update on laboratory diagnostics in Haemophilia A and B, H\u00e4mostaseologie, 42 (4), 2022, 248\u2013260.","DOI":"10.1055\/a-1665-6232"},{"issue":"Suppl 5","key":"10.1016\/j.cll.2026.02.002_bib3","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1365-2516.2010.02295.x","article-title":"New developments in laboratory diagnosis and monitoring","volume":"16","author":"Kitchen","year":"2010","journal-title":"Haemophilia"},{"issue":"5","key":"10.1016\/j.cll.2026.02.002_bib4","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/ijlh.14144","article-title":"Viscoelastic testing: critical appraisal of new methodologies and current literature","volume":"45","author":"Wool","year":"2023","journal-title":"Int J Lab Hematol"},{"issue":"6","key":"10.1016\/j.cll.2026.02.002_bib5","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1111\/jth.14784","article-title":"Laboratory testing in hemophilia: impact of factor and non-factor replacement therapy on coagulation assays","volume":"18","author":"Peyvandi","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.cll.2026.02.002_bib6","author":"Volod"},{"issue":"1","key":"10.1016\/j.cll.2026.02.002_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MBC.0000000000001170","article-title":"Thrombin generation assay: the present and the future","volume":"34","author":"Wu","year":"2023","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.cll.2026.02.002_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.thromres.2024.109045","article-title":"Comparative analysis of thrombin generation platforms for patients with coagulation factor deficiencies: a comprehensive assessment","volume":"240","author":"Haisma","year":"2024","journal-title":"Thromb Res"},{"issue":"6","key":"10.1016\/j.cll.2026.02.002_bib9","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1111\/jth.14786","article-title":"A novel assay for studying the involvement of blood cells in whole blood thrombin generation","volume":"18","author":"Wan","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"11","key":"10.1016\/j.cll.2026.02.002_bib10","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1182\/blood-2012-08-378935","article-title":"Thrombin generation and whole blood viscoelastic assays in the management of hemophilia: current state of art and future perspectives","volume":"121","author":"Young","year":"2013","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.cll.2026.02.002_bib11","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27886","article-title":"Emicizumab prophylaxis among infants and toddlers with severe hemophilia A and inhibitors-a single-center cohort","volume":"66","author":"Barg","year":"2019","journal-title":"Pediatr Blood Cancer"},{"issue":"9","key":"10.1016\/j.cll.2026.02.002_bib12","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have hemophilia A without inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.cll.2026.02.002_bib13","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood-2015-01-528414","article-title":"Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens","volume":"125","author":"Oldenburg","year":"2015","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.cll.2026.02.002_bib14","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/hae.13848","article-title":"A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors","volume":"25","author":"Shima","year":"2019","journal-title":"Haemophilia"},{"key":"10.1016\/j.cll.2026.02.002_bib15","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1182\/blood.V130.Suppl_1.86.86","article-title":"Emicizumab subcutaneous dosing every 4 weeks for the management of Hemophilia A: preliminary data from the pharmacokinetic Run-in cohort of a multicenter, open-label, phase 3 study (HAVEN 4)","volume":"130","author":"Jimenez-Yuste","year":"2017","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.cll.2026.02.002_bib16","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1080\/17474086.2018.1531701","article-title":"Emicizumab for hemophilia A with factor VIII inhibitors","volume":"11","author":"Young","year":"2018","journal-title":"Expert Rev Hematol"},{"issue":"7","key":"10.1016\/j.cll.2026.02.002_bib17","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1055\/s-0039-1688687","article-title":"Effects and interferences of emicizumab, a humanised bispecific antibody mimicking activated factor VIII cofactor function, on coagulation assays","volume":"119","author":"Adamkewicz","year":"2019","journal-title":"Thromb Haemost"},{"issue":"3","key":"10.1016\/j.cll.2026.02.002_bib18","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/hae.13990","article-title":"Effects of emicizumab on APTT, one-stage and chromogenic assays of factor VIII in artificially spiked plasma and in samples from haemophilia A patients with inhibitors","volume":"26","author":"Bowyer","year":"2020","journal-title":"Haemophilia"},{"issue":"5","key":"10.1016\/j.cll.2026.02.002_bib19","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/hae.14359","article-title":"Determining the approximate factor VIII level of patients with severe haemophilia A on emicizumab using in vivo global haemostasis assays","volume":"27","author":"Kizilocak","year":"2021","journal-title":"Haemophilia"},{"issue":"3","key":"10.1016\/j.cll.2026.02.002_bib20","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1055\/s-0040-1717114","article-title":"Pharmacokinetics and pharmacodynamics of emicizumab in persons with hemophilia A with factor VIII inhibitors: HAVEN 1 study","volume":"121","author":"Schmitt","year":"2021","journal-title":"Thromb Haemost"},{"issue":"10386","key":"10.1016\/j.cll.2026.02.002_bib21","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(23)00284-2","article-title":"Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial","volume":"401","author":"Young","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.cll.2026.02.002_bib22","doi-asserted-by":"crossref","first-page":"e322","DOI":"10.1016\/S2352-3026(23)00037-6","article-title":"Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A\/B): a multicentre, open-label, randomised, phase 3 trial","author":"Srivastava","year":"2023","journal-title":"Lancet Haematol"},{"issue":"4","key":"10.1016\/j.cll.2026.02.002_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.100179","article-title":"Antithrombin lowering in hemophilia: a closer look at fitusiran","volume":"7","author":"Young","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"issue":"3","key":"10.1016\/j.cll.2026.02.002_bib25","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/hae.70045","article-title":"Global comparative antithrombin field study: impact of laboratory assay variability on the assessment of antithrombin activity measurement at fitusiran clinical decision-making points","volume":"31","author":"Chhabra","year":"2025","journal-title":"Haemophilia"},{"issue":"22","key":"10.1016\/j.cll.2026.02.002_bib26","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1182\/blood.2019001542","article-title":"Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A\/B with inhibitors: phase 2 trial results","volume":"134","author":"Shapiro","year":"2019","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.cll.2026.02.002_bib27","doi-asserted-by":"crossref","first-page":"3422","DOI":"10.1182\/bloodadvances.2021006403","article-title":"Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A\/B with inhibitors","volume":"6","author":"Shapiro","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.cll.2026.02.002_bib28","unstructured":"Wheeler A.P., Shapiro A., Porstmann V., et al., Risk mitigation during concizumab prophylaxis in phase 3 clinial trials in patients with hemophilia A\/B with and without inhibitors: managemet of breakthrough bleeds and dose optimization [abstract], Am J Hematol, 98 (Suppl 1), 2023, E118\u2013E119."},{"issue":"4","key":"10.1016\/j.cll.2026.02.002_bib30","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1111\/hae.15070","article-title":"Minimal interference of concizumab with standard clinical coagulation laboratory assays - an in vitro study","volume":"30","author":"Augustsson","year":"2024","journal-title":"Haemophilia"},{"key":"10.1016\/j.cll.2026.02.002_bib32","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/bjh.18420","article-title":"A phase 1b\/2 clinical study of marstacimab, targeting human tissue factor pathway inhibitor, in haemophilia","author":"Mahlangu","year":"2023","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.cll.2026.02.002_bib33","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/hae.13820","article-title":"Marstacimab, a tissue factor pathway inhibitor neutralizing antibody, improves coagulation parameters of ex vivo dosed haemophilic blood and plasmas","volume":"25","author":"Patel-Hett","year":"2019","journal-title":"Haemophilia"},{"issue":"2","key":"10.1016\/j.cll.2026.02.002_bib34","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12679","article-title":"Hemostatic efficacy of marstacimab alone or in combination with bypassing agents in hemophilia plasmas and a mouse bleeding model","volume":"6","author":"Pittman","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"issue":"3","key":"10.1016\/j.cll.2026.02.002_bib36","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.jtha.2022.12.023","article-title":"The effect of a next generation factor VIII mimetic bispecific antibody (Mim8) on assays of factor VIII activity and thrombin generation","volume":"21","author":"Bowyer","year":"2023","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.cll.2026.02.002_bib37","unstructured":"Windyga J, et al, Mim8 is associated with improved thrombin generation vs. emicizumab in patients with haemophilia A, with and without inhibitors (abstract), in ISTH. 2022: London, UK."},{"key":"10.1016\/j.cll.2026.02.002_bib38","series-title":"ISTH annual Congress","article-title":"Efficacy and safety of Mim8 prophylaxis in adults and adolescents with hemophilia A with or without inhibitors: phase 3, open-label, randomized, controlled FRONTIER2 study","author":"Mancuso","year":"2024"},{"key":"10.1016\/j.cll.2026.02.002_bib39","doi-asserted-by":"crossref","unstructured":"Matsushita T, et al, Safety and efficacy of Mim8 prophylaxis administered once every two weeks for patients with hemophilia a with or without inhibitors: interim analysis of the FRONTIER4 open-label extension study, in ASH 66th Annual Meeting. 2024: San Diego, CA.","DOI":"10.1182\/blood-2024-198617"},{"issue":"11","key":"10.1016\/j.cll.2026.02.002_bib40","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMoa2002699","article-title":"BIVV001 fusion protein as factor VIII replacement therapy for Hemophilia A","volume":"383","author":"Konkle","year":"2020","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.cll.2026.02.002_bib41","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1111\/jth.15741","article-title":"Efanesoctocog alfa elicits functional clot formation that is indistinguishable to that of recombinant factor VIII","volume":"20","author":"Demers","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"17","key":"10.1016\/j.cll.2026.02.002_bib42","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1182\/blood.2019001292","article-title":"BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice","volume":"135","author":"Seth Chhabra","year":"2020","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.cll.2026.02.002_bib43","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2209226","article-title":"Efanesoctocog Alfa prophylaxis for patients with severe Hemophilia A","volume":"388","author":"von Drygalski","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.cll.2026.02.002_bib44","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/hae.14831","article-title":"A global comparative field study to evaluate the factor VIII activity of efanesoctocog alfa by one-stage clotting and chromogenic substrate assays at clinical haemostasis laboratories","volume":"30","author":"Pipe","year":"2024","journal-title":"Haemophilia"},{"issue":"4","key":"10.1016\/j.cll.2026.02.002_bib45","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/jth.14394","article-title":"Laboratory assay measurement of modified clotting factor concentrates: a review of the literature and recommendations for practice","volume":"17","author":"Young","year":"2019","journal-title":"J Thromb Haemost"},{"issue":"22","key":"10.1016\/j.cll.2026.02.002_bib46","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1182\/blood.2020005683","article-title":"Activity of transgene-produced B-domain-deleted factor VIII in human plasma following AAV5 gene therapy","volume":"136","author":"Rosen","year":"2020","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.cll.2026.02.002_bib48","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/hae.70053","article-title":"Evaluation of one-stage assays for the monitoring of recombinant human factor IX padua activity after etranacogene dezaparvovec gene therapy","volume":"31","author":"Astermark","year":"2025","journal-title":"Haemophilia"},{"issue":"11","key":"10.1016\/j.cll.2026.02.002_bib50","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1182\/blood.2019003777","article-title":"Gene therapy for hemophilia: a review on clinical benefit, limitations, and remaining issues","volume":"138","author":"Leebeek","year":"2021","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.cll.2026.02.002_bib51","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1182\/blood-2017-09-804419","article-title":"Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B","volume":"131","author":"Miesbach","year":"2018","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.cll.2026.02.002_bib52","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1016\/j.jtha.2024.04.001","article-title":"Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A","volume":"22","author":"Madan","year":"2024","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.1016\/j.cll.2026.02.002_bib53","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/hae.14936","article-title":"Long-term safety and efficacy outcomes of valoctocogene roxaparvovec gene transfer up to 6 years post-treatment","volume":"30","author":"Symington","year":"2024","journal-title":"Haemophilia"},{"issue":"25","key":"10.1016\/j.cll.2026.02.002_bib54","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-associated virus vector-mediated gene transfer in hemophilia B","volume":"365","author":"Nathwani","year":"2011","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.cll.2026.02.002_bib55","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1182\/bloodadvances.2024015291","article-title":"Completion of phase 2b trial of etranacogene dezaparvovec gene therapy in patients with hemophilia B over 5 years","volume":"9","author":"von Drygalski","year":"2025","journal-title":"Blood Adv"}],"container-title":["Clinics in Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272271226000028?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272271226000028?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T18:03:03Z","timestamp":1783620183000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272271226000028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0272271226000028"],"URL":"https:\/\/doi.org\/10.1016\/j.cll.2026.02.002","relation":{},"ISSN":["0272-2712"],"issn-type":[{"value":"0272-2712","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in Hemophilia: New Treatments and Complications in Laboratory Testing\/Monitoring","name":"articletitle","label":"Article Title"},{"value":"Clinics in Laboratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cll.2026.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}